Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/13543784.17.5.811
Reference60 articles.
1. Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study
2. Perception of the Role and Potential Side Effects of Inhaled Corticosteroids Among Asthmatic Patients
3. Trends in the Leading Causes of Death in the United States, 1970-2002
4. Airway Inflammation in Severe Chronic Obstructive Pulmonary Disease
5. Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should)
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. 14-3-3 interaction with phosphodiesterase 8A sustains PKA signaling and downregulates the MAPK pathway;Journal of Biological Chemistry;2024-03
2. Carbon 14 and stable isotope synthesis of two potent and selective phosphodiesterase type 4 inhibitors;Journal of Labelled Compounds and Radiopharmaceuticals;2023-07-24
3. Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26
4. Electrochemical Behavior and Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms;Combinatorial Chemistry & High Throughput Screening;2021-03
5. Curious effects of fluorine on medicinally active compounds;The Curious World of Fluorinated Molecules;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3